Why the study?
Does verapamil improve exercise capacity and left ventricular function compared to propranolol and placebo in patients with stable effort angina?
Does verapamil improve exercise capacity and left ventricular function compared to propranolol and placebo in patients with stable effort angina?
Verapamil is an effective alternative to propranolol for improving exercise capacity and left ventricular function in patients with stable effort angina.
Answers are grounded in this paper and cite their sources.
Verapamil offers a comparable alternative to propranolol in stable angina; reinforces calcium channel blockade as effective therapy.
In 18 patients with stable effort angina, verapamil, 80 mg four times daily, was compared with propranolol, 80 mg four times daily, in a double-blind, placebo-controlled trial to assess the effects on anginal threshold, exercise capacity and left ventricular function measured by gated equilibrium blood pool scanning. Both propranolol and verapamil improved exercise capacity (placebo 424 +/- 135 W-min; propranolol 513 +/- 168 W-min, p less than 0.01; verapamil 545 +/- 215 W-min, p less than 0.005) and prolonged the time to 1 mm of ST depression (placebo 4.5 +/- 1.3 minutes; propranolol 7.4 +/- 1.4 minutes, p less than 0.005; verapamil 6.6 +/- 1.9 minutes, p less than 0.005). At rest, the mean left ventricular ejection fraction did not change significantly during drug therapy (placebo 57 +/- 13%, propranolol 55 +/- 12%, verapamil 55 +/- 13%). While taking placebo, all 18 patients had a decrease in exercise ejection fraction. In contrast, 12 patients taking propranolol and 14 patients taking verapamil had a 5% or greater increase in ejection fraction during exercise. Verapamil is an effective primary therapy and a satisfactory alternative to propranolol in patients with stable effort angina.
No takes yet. Share an insight, caveat, or question.
Sadick et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: